{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T17:08:56Z","timestamp":1794676136403,"version":"4.9.1"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41571-023-00832-4","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:02:06Z","timestamp":1698670926000},"page":"47-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":559,"title":["CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-3752","authenticated-orcid":false,"given":"Steven M.","family":"Albelda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"832_CR1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"832_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"832_CR3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"832_CR4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"832_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh, R. H. & Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275\u2013285 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"832_CR6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"832_CR7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner, A., Corrie, P. G. & Hamid, O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin. Cancer Res. 29, 1835\u20131854 (2023).","journal-title":"Clin. Cancer Res."},{"key":"832_CR8","doi-asserted-by":"crossref","first-page":"ltab004","DOI":"10.1093\/immadv\/ltab004","volume":"1","author":"A Adami","year":"2021","unstructured":"Adami, A. & Maher, J. An overview of CAR T-cell clinical trial activity to 2021. Immunother. Adv. 1, ltab004 (2021).","journal-title":"Immunother. Adv."},{"key":"832_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel, U. et al. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem 3, 24\u201331 (2022).","journal-title":"EJHaem"},{"key":"832_CR10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"832_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139\u2013152 (2017).","journal-title":"Annu. Rev. Med."},{"key":"832_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Riviere, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"832_CR13","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","volume":"9","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann, H. M. et al. CAR T cells in solid tumors: blueprints for building effective therapies. Front. Immunol. 9, 1740 (2018).","journal-title":"Front. Immunol."},{"key":"832_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).","journal-title":"Front. Immunol."},{"key":"832_CR15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"832_CR16","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner, J., Wickman, E., DeRenzo, C. & Gottschalk, S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol. Ther. 28, 2320\u20132339 (2020).","journal-title":"Mol. Ther."},{"key":"832_CR17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002555","volume":"9","author":"DG Tantalo","year":"2021","unstructured":"Tantalo, D. G. et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J. Immunother. Cancer 9, e002555 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"832_CR18","doi-asserted-by":"crossref","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber, D. & Wang, L. D. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine 77, 103941 (2022).","journal-title":"EBioMedicine"},{"key":"832_CR19","doi-asserted-by":"crossref","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G Lopez-Cantillo","year":"2022","unstructured":"Lopez-Cantillo, G., Uruena, C., Camacho, B. A. & Ramirez-Segura, C. CAR-T cell performance: how to improve their persistence? Front. Immunol. 13, 878209 (2022).","journal-title":"Front. Immunol."},{"key":"832_CR20","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00432-022-04547-4","volume":"149","author":"K Drougkas","year":"2023","unstructured":"Drougkas, K. et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? J. Cancer Res. Clin. Oncol. 149, 2709\u20132734 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"832_CR21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/cancers15041171","volume":"15","author":"J Maher","year":"2023","unstructured":"Maher, J. & Davies, D. M. CAR-based immunotherapy of solid tumours \u2013 a survey of the emerging targets. Cancers 15, 1171 (2023).","journal-title":"Cancers"},{"key":"832_CR22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"832_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26\u201331 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR24","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"832_CR25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"832_CR26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"832_CR27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett, T. et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther. 24, 1135\u20131149 (2016).","journal-title":"Mol. Ther."},{"key":"832_CR28","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"832_CR29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"832_CR30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"832_CR31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"832_CR32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","volume":"71","author":"GEP Box","year":"1976","unstructured":"Box, G. E. P. Science and statistics. J. Am. Stat. Assoc. 71, 791\u2013799 (1976).","journal-title":"J. Am. Stat. Assoc."},{"key":"832_CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","volume":"27","author":"BB Duncan","year":"2022","unstructured":"Duncan, B. B., Dunbar, C. E. & Ishii, K. Applying a clinical lens to animal models of CAR-T cell therapies. Mol. Ther. Methods Clin. Dev. 27, 17\u201331 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"832_CR34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.omto.2020.07.005","volume":"18","author":"A Klampatsa","year":"2020","unstructured":"Klampatsa, A. et al. Analysis and augmentation of the immunologic bystander effects of CAR T cell therapy in a syngeneic mouse cancer model. Mol. Ther. Oncolytics 18, 360\u2013371 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"832_CR35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S. et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39, 193\u2013208.e10 (2021).","journal-title":"Cancer Cell"},{"key":"832_CR36","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"832_CR37","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3390\/cancers12071915","volume":"12","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly, R. & Verhoeyen, E. Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies. Cancers 12, 1915 (2020).","journal-title":"Cancers"},{"key":"832_CR38","doi-asserted-by":"crossref","first-page":"20201013","DOI":"10.1098\/rsif.2020.1013","volume":"18","author":"LV Brown","year":"2021","unstructured":"Brown, L. V., Gaffney, E. A., Ager, A., Wagg, J. & Coles, M. C. Quantifying the limits of CAR T-cell delivery in mice and men. J. R. Soc. Interface 18, 20201013 (2021).","journal-title":"J. R. Soc. Interface"},{"key":"832_CR39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2967\/jnumed.115.159855","volume":"56","author":"MA Moroz","year":"2015","unstructured":"Moroz, M. A. et al. Comparative analysis of T cell imaging with human nuclear reporter genes. J. Nucl. Med. 56, 1055\u20131060 (2015).","journal-title":"J. Nucl. Med."},{"key":"832_CR40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.omto.2021.06.006","volume":"22","author":"MS Skovgard","year":"2021","unstructured":"Skovgard, M. S. et al. Imaging CAR T-cell kinetics in solid tumors: translational implications. Mol. Ther. Oncolytics 22, 355\u2013367 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"832_CR41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2326-6066.CIR-20-0678","volume":"9","author":"Z Xiao","year":"2021","unstructured":"Xiao, Z. & Pure, E. Imaging of T-cell responses in the context of cancer immunotherapy. Cancer Immunol. Res. 9, 490\u2013502 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.drudis.2021.10.012","volume":"27","author":"J Van Hoeck","year":"2022","unstructured":"Van Hoeck, J., Vanhove, C., De Smedt, S. C. & Raemdonck, K. Non-invasive cell-tracking methods for adoptive T cell therapies. Drug. Discov. Today 27, 793\u2013807 (2022).","journal-title":"Drug. Discov. Today"},{"key":"832_CR43","doi-asserted-by":"crossref","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","volume":"9","author":"KV Keu","year":"2017","unstructured":"Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci. Transl. Med. 9, eaag2196 (2017).","journal-title":"Sci. Transl. Med."},{"key":"832_CR44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/2326-6066.CIR-20-0901","volume":"9","author":"R Sakemura","year":"2021","unstructured":"Sakemura, R. et al. Development of a clinically relevant reporter for chimeric antigen receptor T-cell expansion, trafficking, and toxicity. Cancer Immunol. Res. 9, 1035\u20131046 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR45","doi-asserted-by":"crossref","first-page":"eaaw5096","DOI":"10.1126\/sciadv.aaw5096","volume":"5","author":"I Minn","year":"2019","unstructured":"Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci. Adv. 5, eaaw5096 (2019).","journal-title":"Sci. Adv."},{"key":"832_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","volume":"28","author":"MA Sellmyer","year":"2020","unstructured":"Sellmyer, M. A. et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Mol. Ther. 28, 42\u201351 (2020).","journal-title":"Mol. Ther."},{"key":"832_CR47","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon, E. K. et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 20, 4262\u20134273 (2014).","journal-title":"Clin. Cancer Res."},{"key":"832_CR48","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Disruption of desmoplastic stroma overcomes restrictions to T cell extravasation, immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023).","journal-title":"Nat. Commun."},{"key":"832_CR49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C. & Restifo, N. P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26, 111\u2013117 (2005).","journal-title":"Trends Immunol."},{"key":"832_CR50","volume":"3","author":"K Watanabe","year":"2018","unstructured":"Watanabe, K. et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 3, e99573 (2018).","journal-title":"JCI Insight"},{"key":"832_CR51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.1989.7.2.250","volume":"7","author":"B Fisher","year":"1989","unstructured":"Fisher, B. et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250\u2013261 (1989).","journal-title":"J. Clin. Oncol."},{"key":"832_CR52","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jnci\/81.22.1709","volume":"81","author":"KD Griffith","year":"1989","unstructured":"Griffith, K. D. et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl Cancer Inst. 81, 1709\u20131717 (1989).","journal-title":"J. Natl Cancer Inst."},{"key":"832_CR53","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H","volume":"73","author":"BA Pockaj","year":"1994","unstructured":"Pockaj, B. A. et al. Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73, 1731\u20131737 (1994).","journal-title":"Cancer"},{"key":"832_CR54","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.170.4.2161","volume":"170","author":"N Meidenbauer","year":"2003","unstructured":"Meidenbauer, N. et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170, 2161\u20132169 (2003).","journal-title":"J. Immunol."},{"key":"832_CR55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00262-007-0355-7","volume":"57","author":"H Bernhard","year":"2008","unstructured":"Bernhard, H. et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57, 271\u2013280 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"832_CR56","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"832_CR57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007162","volume":"11","author":"S Papa","year":"2023","unstructured":"Papa, S. et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J. Immunother. Cancer 11, e007162 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"832_CR58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/BST20150254","volume":"44","author":"A Ager","year":"2016","unstructured":"Ager, A., Watson, H. A., Wehenkel, S. C. & Mohammed, R. N. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem. Soc. Trans. 44, 377\u2013385 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"832_CR59","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/labinvest.2017.25","volume":"97","author":"R Sackstein","year":"2017","unstructured":"Sackstein, R., Schatton, T. & Barthel, S. R. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab. Invest. 97, 669\u2013697 (2017).","journal-title":"Lab. Invest."},{"key":"832_CR60","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3389\/fimmu.2018.03084","volume":"9","author":"R Sackstein","year":"2018","unstructured":"Sackstein, R. The first step in adoptive cell immunotherapeutics: assuring cell delivery via glycoengineering. Front. Immunol. 9, 3084 (2018).","journal-title":"Front. Immunol."},{"key":"832_CR61","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/vaccines10111845","volume":"10","author":"S Michaelides","year":"2022","unstructured":"Michaelides, S., Obeck, H., Kechur, D., Endres, S. & Kobold, S. Migratory engineering of T cells for cancer therapy. Vaccines 10, 1845 (2022).","journal-title":"Vaccines"},{"key":"832_CR62","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cancers14040978","volume":"14","author":"LG White","year":"2022","unstructured":"White, L. G., Goy, H. E., Rose, A. J. & McLellan, A. D. Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers 14, 978 (2022).","journal-title":"Cancers"},{"key":"832_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00281-023-00983-7","volume":"45","author":"D Espie","year":"2023","unstructured":"Espie, D. & Donnadieu, E. CAR T-cell behavior and function revealed by real-time imaging. Semin. Immunopathol. 45, 229\u2013239 (2023).","journal-title":"Semin. Immunopathol."},{"key":"832_CR64","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1158\/2326-6066.CIR-20-0837","volume":"9","author":"C Kantari-Mimoun","year":"2021","unstructured":"Kantari-Mimoun, C. et al. CAR T-cell entry into tumor islets is a two-step process dependent on IFN\u03b3 and ICAM-1. Cancer Immunol. Res. 9, 1425\u20131438 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"832_CR66","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.194.7.953","volume":"194","author":"W Weninger","year":"2001","unstructured":"Weninger, W., Crowley, M. A., Manjunath, N. & von Andrian, U. H. Migratory properties of naive, effector, and memory CD8+ T cells. J. Exp. Med. 194, 953\u2013966 (2001).","journal-title":"J. Exp. Med."},{"key":"832_CR67","volume":"20","author":"H Choi","year":"2020","unstructured":"Choi, H., Song, H. & Jung, Y. W. The roles of CCR7 for the homing of memory CD8+ T cells into their survival niches. Immune Netw. 20, e20 (2020).","journal-title":"Immune Netw."},{"key":"832_CR68","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/CJI.0b013e31822bc3d0","volume":"34","author":"JM Faint","year":"2011","unstructured":"Faint, J. M., Tuncer, C., Garg, A., Adams, D. H. & Lalor, P. F. Functional consequences of human lymphocyte cryopreservation: implications for subsequent interactions of cells with endothelium. J. Immunother. 34, 588\u2013596 (2011).","journal-title":"J. Immunother."},{"key":"832_CR69","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3389\/fimmu.2019.01321","volume":"10","author":"HA Watson","year":"2019","unstructured":"Watson, H. A. et al. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Front. Immunol. 10, 1321 (2019).","journal-title":"Front. Immunol."},{"key":"832_CR70","volume":"4","author":"W Zhu","year":"2015","unstructured":"Zhu, W. et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality. Oncoimmunology 4, e1051922 (2015).","journal-title":"Oncoimmunology"},{"key":"832_CR71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"832_CR72","volume":"5","author":"PH Chen","year":"2020","unstructured":"Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020).","journal-title":"JCI Insight"},{"key":"832_CR73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1535-7163.MCT-21-0506","volume":"22","author":"NE Olson","year":"2023","unstructured":"Olson, N. E. et al. Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel. Mol. Cancer Ther. 22, 406\u2013418 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"832_CR74","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"832_CR75","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"832_CR76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"832_CR77","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"832_CR78","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/cancers14041078","volume":"14","author":"A Titov","year":"2022","unstructured":"Titov, A. et al. Knowns and unknowns about CAR-T cell dysfunction. Cancers 14, 1078 (2022).","journal-title":"Cancers"},{"key":"832_CR79","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e26 (2021).","journal-title":"Cell"},{"key":"832_CR80","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/ijms20235821","volume":"20","author":"P Sitaram","year":"2019","unstructured":"Sitaram, P., Uyemura, B., Malarkannan, S. & Riese, M. J. Beyond the cell surface: targeting intracellular negative regulators to enhance T cell anti-tumor activity. Int. J. Mol. Sci. 20, 5821 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"832_CR81","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).","journal-title":"Sci. Transl. Med."},{"key":"832_CR82","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142030","volume":"131","author":"E Roselli","year":"2021","unstructured":"Roselli, E., Faramand, R. & Davila, M. L. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J. Clin. Invest. 131, e142030 (2021).","journal-title":"J. Clin. Invest."},{"key":"832_CR83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","volume":"51","author":"N Chen","year":"2018","unstructured":"Chen, N., Li, X., Chintala, N. K., Tano, Z. E. & Adusumilli, P. S. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr. Opin. Immunol. 51, 103\u2013110 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"832_CR84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/2326-6066.CIR-19-0801","volume":"8","author":"SM Albelda","year":"2020","unstructured":"Albelda, S. M. Tumor antigen heterogeneity: the \u201celephant in the room\u201d of adoptive T-cell therapy for solid tumors. Cancer Immunol. Res. 8, 2 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR85","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"832_CR86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.20517\/2394-4722.2022.51","volume":"8","author":"RR D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, R. R. et al. Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM). J. Cancer Metastasis Treat. 8, 28 (2022).","journal-title":"J. Cancer Metastasis Treat."},{"key":"832_CR87","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"832_CR88","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085 (2021).","journal-title":"Blood"},{"key":"832_CR89","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"832_CR90","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"832_CR91","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"832_CR92","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","volume":"9","author":"M Feuerer","year":"2003","unstructured":"Feuerer, M. et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat. Med. 9, 1151\u20131157 (2003).","journal-title":"Nat. Med."},{"key":"832_CR93","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Invest."},{"key":"832_CR94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","volume":"9","author":"E Zhao","year":"2012","unstructured":"Zhao, E. et al. Bone marrow and the control of immunity. Cell Mol. Immunol. 9, 11\u201319 (2012).","journal-title":"Cell Mol. Immunol."},{"key":"832_CR95","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"832_CR96","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"832_CR97","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"832_CR98","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/cancers13174301","volume":"13","author":"M Csaplar","year":"2021","unstructured":"Csaplar, M., Szollosi, J., Gottschalk, S., Vereb, G. & Szoor, A. Cytolytic activity of CAR T cells and maintenance of their CD4+ subset is critical for optimal antitumor activity in preclinical solid tumor models. Cancers 13, 4301 (2021).","journal-title":"Cancers"},{"key":"832_CR99","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers13051050","volume":"13","author":"A Textor","year":"2021","unstructured":"Textor, A. et al. CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus. Cancers 13, 1050 (2021).","journal-title":"Cancers"},{"key":"832_CR100","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP Bottcher","year":"2018","unstructured":"Bottcher, J. P., Reis, E. & Sousa, C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784\u2013792 (2018).","journal-title":"Trends Cancer"},{"key":"832_CR101","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"AD McLellan","year":"2019","unstructured":"McLellan, A. D. & Ali Hosseini Rad, S. M. Chimeric antigen receptor T cell persistence and memory cell formation. Immunol. Cell Biol. 97, 664\u2013674 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"832_CR102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769\u2013784 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"832_CR103","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.4049\/jimmunol.173.12.7125","volume":"173","author":"PF Robbins","year":"2004","unstructured":"Robbins, P. F. et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125\u20137130 (2004).","journal-title":"J. Immunol."},{"key":"832_CR104","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"832_CR105","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"832_CR106","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","volume":"11","author":"L Jafarzadeh","year":"2020","unstructured":"Jafarzadeh, L., Masoumi, E., Fallah-Mehrjardi, K., Mirzaei, H. R. & Hadjati, J. Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward. Front. Immunol. 11, 702 (2020).","journal-title":"Front. Immunol."},{"key":"832_CR107","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/ijms24065688","volume":"24","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager, V. et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int. J. Mol. Sci. 24, 5688 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"832_CR108","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","volume":"132","author":"NP Kristensen","year":"2022","unstructured":"Kristensen, N. P. et al. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J. Clin. Invest. 132, e150535 (2022).","journal-title":"J. Clin. Invest."},{"key":"832_CR109","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"832_CR110","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"832_CR111","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.omtn.2023.04.012","volume":"32","author":"KM Fichter","year":"2023","unstructured":"Fichter, K. M., Setayesh, T. & Malik, P. Strategies for precise gene edits in mammalian cells. Mol. Ther. Nucleic Acids 32, 536\u2013552 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"832_CR112","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"832_CR113","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","volume":"23","author":"A Minagawa","year":"2018","unstructured":"Minagawa, A. et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell 23, 850\u2013858.e4 (2018).","journal-title":"Cell Stem Cell"},{"key":"832_CR114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.12.006","volume":"16","author":"S Nagano","year":"2020","unstructured":"Nagano, S. et al. High frequency production of T cell-derived iPSC clones capable of generating potent cytotoxic T cells. Mol. Ther. Methods Clin. Dev. 16, 126\u2013135 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"832_CR115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00005-021-00640-7","volume":"70","author":"R Mazza","year":"2021","unstructured":"Mazza, R. & Maher, J. Prospects for development of induced pluripotent stem cell-derived CAR-targeted immunotherapies. Arch. Immunol. Ther. Exp. 70, 2 (2021).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"832_CR116","doi-asserted-by":"crossref","first-page":"759558","DOI":"10.3389\/fimmu.2021.759558","volume":"12","author":"R Netsrithong","year":"2021","unstructured":"Netsrithong, R. & Wattanapanitch, M. Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells. Front. Immunol. 12, 759558 (2021).","journal-title":"Front. Immunol."},{"key":"832_CR117","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/cells11020269","volume":"11","author":"Y Furukawa","year":"2022","unstructured":"Furukawa, Y. et al. Advances in allogeneic cancer cell therapy and future perspectives on \u201coff-the-shelf\u201d T cell therapy using iPSC technology and gene editing. Cells 11, 269 (2022).","journal-title":"Cells"},{"key":"832_CR118","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","volume":"6","author":"SJC van der Stegen","year":"2022","unstructured":"van der Stegen, S. J. C. et al. Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nat. Biomed. Eng. 6, 1284\u20131297 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"832_CR119","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20658-3","volume":"12","author":"S Iriguchi","year":"2021","unstructured":"Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 430 (2021).","journal-title":"Nat. Commun."},{"issue":"Suppl. 2","key":"832_CR120","first-page":"A319","volume":"10","author":"M Hosking","year":"2022","unstructured":"Hosking, M. et al. Off-the-shelf iPSC-derived CAR-T cells containing seven functional edits overcome antigen heterogeneity, improve trafficking, and withstand immunosuppression associated with failed tumor treatment. Soc. Immunother [abstract 304]. Cancer 10 (Suppl. 2), A319 (2022).","journal-title":"Cancer"},{"key":"832_CR121","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360\u20133365 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"832_CR122","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/sj.leu.2403463","volume":"18","author":"E Smits","year":"2004","unstructured":"Smits, E. et al. RNA-based gene transfer for adult stem cells and T cells. Leukemia 18, 1898\u20131902 (2004).","journal-title":"Leukemia"},{"key":"832_CR123","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053\u20139061 (2010).","journal-title":"Cancer Res."},{"key":"832_CR124","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","volume":"24","author":"DM Barrett","year":"2013","unstructured":"Barrett, D. M. et al. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum. Gene Ther. 24, 717\u2013727 (2013).","journal-title":"Hum. Gene Ther."},{"key":"832_CR125","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian, S. S. et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29, 1637\u20131647 (2015).","journal-title":"Leukemia"},{"key":"832_CR126","doi-asserted-by":"crossref","first-page":"28911","DOI":"10.18632\/oncotarget.5029","volume":"6","author":"K Schutsky","year":"2015","unstructured":"Schutsky, K. et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget 6, 28911\u201328928 (2015).","journal-title":"Oncotarget"},{"key":"832_CR127","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1089\/hum.2017.080","volume":"29","author":"CF Hung","year":"2018","unstructured":"Hung, C. F. et al. Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA-transfected peripheral blood lymphocytes for ovarian cancer therapy. Hum. Gene Ther. 29, 614\u2013625 (2018).","journal-title":"Hum. Gene Ther."},{"key":"832_CR128","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","volume":"27","author":"JB Foster","year":"2019","unstructured":"Foster, J. B., Barrett, D. M. & Kariko, K. The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy. Mol. Ther. 27, 747\u2013756 (2019).","journal-title":"Mol. Ther."},{"key":"832_CR129","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.3390\/ijms21186514","volume":"21","author":"T Soundara Rajan","year":"2020","unstructured":"Soundara Rajan, T., Gugliandolo, A., Bramanti, P. & Mazzon, E. In vitro-transcribed mRNA chimeric antigen receptor T cell (IVT mRNA CAR T) therapy in hematologic and solid tumor management: a preclinical update. Int. J. Mol. Sci. 21, 6514 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"832_CR130","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752\u2013763 (2021).","journal-title":"Leukemia"},{"key":"832_CR131","doi-asserted-by":"crossref","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti, A. et al. The past, present, and future of non-viral CAR T cells. Front. Immunol. 13, 867013 (2022).","journal-title":"Front. Immunol."},{"key":"832_CR132","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112\u2013120 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR133","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"832_CR134","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/14653249.2010.542461","volume":"13","author":"H Almasbak","year":"2011","unstructured":"Almasbak, H. et al. Transiently redirected T cells for adoptive transfer. Cytotherapy 13, 629\u2013640 (2011).","journal-title":"Cytotherapy"},{"key":"832_CR135","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","volume":"28","author":"H Meister","year":"2022","unstructured":"Meister, H. et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin. Cancer Res. 28, 4747\u20134756 (2022).","journal-title":"Clin. Cancer Res."},{"key":"832_CR136","doi-asserted-by":"crossref","first-page":"111160","DOI":"10.1016\/j.celrep.2022.111160","volume":"40","author":"L Peng","year":"2022","unstructured":"Peng, L. et al. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Rep. 40, 111160 (2022).","journal-title":"Cell Rep."},{"key":"832_CR137","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","volume":"23","author":"NN Parayath","year":"2021","unstructured":"Parayath, N. N. & Stephan, M. T. In situ programming of CAR T cells. Annu. Rev. Biomed. Eng. 23, 385\u2013405 (2021).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"832_CR138","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"832_CR139","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/08820139.2017.1280052","volume":"46","author":"Y Cao","year":"2017","unstructured":"Cao, Y., Huang, H., Wang, Z. & Zhang, G. The inflammatory CXC chemokines, GRO\u03b1high, IP-10low, and MIGlow, in tumor microenvironment can be used as new indicators for non-small cell lung cancer progression. Immunol. Invest. 46, 361\u2013374 (2017).","journal-title":"Immunol. Invest."},{"key":"832_CR140","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","volume":"4","author":"K Newick","year":"2016","unstructured":"Newick, K. et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol. Res. 4, 541\u2013551 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR141","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2015.11.003","volume":"28","author":"PA Beavis","year":"2016","unstructured":"Beavis, P. A. et al. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin. Immunol. 28, 64\u201372 (2016).","journal-title":"Semin. Immunol."},{"key":"832_CR142","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719\u20134730 (2011).","journal-title":"Clin. Cancer Res."},{"key":"832_CR143","volume":"7","author":"EK Moon","year":"2018","unstructured":"Moon, E. K. et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7, e1395997 (2018).","journal-title":"Oncoimmunology"},{"key":"832_CR144","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","volume":"184","author":"LR Johnson","year":"2021","unstructured":"Johnson, L. R. et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell 184, 4981\u20134995.e14 (2021).","journal-title":"Cell"},{"key":"832_CR145","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"832_CR146","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19, 751\u2013759 (2011).","journal-title":"Mol. Ther."},{"key":"832_CR147","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"832_CR148","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fonc.2019.00241","volume":"9","author":"S Di","year":"2019","unstructured":"Di, S. et al. Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells. Front. Oncol. 9, 241 (2019).","journal-title":"Front. Oncol."},{"key":"832_CR149","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/0008-5472.CAN-14-2467","volume":"75","author":"D Geng","year":"2015","unstructured":"Geng, D. et al. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 75, 1959\u20131971 (2015).","journal-title":"Cancer Res."},{"key":"832_CR150","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-18-1527","volume":"25","author":"G Alatrash","year":"2019","unstructured":"Alatrash, G. et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin. Cancer Res. 25, 2610\u20132620 (2019).","journal-title":"Clin. Cancer Res."},{"key":"832_CR151","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1074\/jbc.RA119.011134","volume":"294","author":"N Mondal","year":"2019","unstructured":"Mondal, N., Silva, M., Castano, A. P., Maus, M. V. & Sackstein, R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. J. Biol. Chem. 294, 18465\u201318474 (2019).","journal-title":"J. Biol. Chem."},{"key":"832_CR152","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.smim.2020.101417","volume":"48","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly, R. & Mechta-Grigoriou, F. Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies. Semin. Immunol. 48, 101417 (2020).","journal-title":"Semin. Immunol."},{"key":"832_CR153","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen, Y., McAndrews, K. M. & Kalluri, R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat. Rev. Clin. Oncol. 18, 792\u2013804 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"832_CR154","doi-asserted-by":"crossref","first-page":"791453","DOI":"10.3389\/fimmu.2021.791453","volume":"12","author":"AMA Romer","year":"2021","unstructured":"Romer, A. M. A., Thorseth, M. L. & Madsen, D. H. Immune modulatory properties of collagen in cancer. Front. Immunol. 12, 791453 (2021).","journal-title":"Front. Immunol."},{"key":"832_CR155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"832_CR156","doi-asserted-by":"crossref","first-page":"660488","DOI":"10.3389\/fimmu.2021.660488","volume":"12","author":"R Zhao","year":"2021","unstructured":"Zhao, R. et al. Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer. Front. Immunol. 12, 660488 (2021).","journal-title":"Front. Immunol."},{"key":"832_CR157","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","volume":"8","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Bioorthogonal equipping CAR-T cells with hyaluronidase and checkpoint blocking antibody for enhanced solid tumor immunotherapy. ACS Cent. Sci. 8, 603\u2013614 (2022).","journal-title":"ACS Cent. Sci."},{"key":"832_CR158","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR159","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","volume":"75","author":"A Lo","year":"2015","unstructured":"Lo, A. et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75, 2800\u20132810 (2015).","journal-title":"Cancer Res."},{"key":"832_CR160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda, R., Dimou, P., D\u2019Souza, R. R. & Klampatsa, A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 10, 313\u2013323 (2021).","journal-title":"Immunotargets Ther."},{"key":"832_CR161","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1158\/1078-0432.CCR-22-1379","volume":"28","author":"IK Lee","year":"2022","unstructured":"Lee, I. K. et al. Monitoring therapeutic response to anti-FAP CAR T cells using [18F]AlF-FAPI-74. Clin. Cancer Res. 28, 5330\u20135342 (2022).","journal-title":"Clin. Cancer Res."},{"key":"832_CR162","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J. Transl. Med. 21, 255 (2023).","journal-title":"J. Transl. Med."},{"key":"832_CR163","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125\u20131135 (2013).","journal-title":"J. Exp. Med."},{"key":"832_CR164","doi-asserted-by":"crossref","first-page":"82354","DOI":"10.18632\/oncotarget.10510","volume":"7","author":"XJ Xu","year":"2016","unstructured":"Xu, X. J. et al. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. Oncotarget 7, 82354\u201382368 (2016).","journal-title":"Oncotarget"},{"key":"832_CR165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","volume":"19","author":"T Kaartinen","year":"2017","unstructured":"Kaartinen, T. et al. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 19, 689\u2013702 (2017).","journal-title":"Cytotherapy"},{"key":"832_CR166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature24993","volume":"552","author":"JJ Milner","year":"2017","unstructured":"Milner, J. J. et al. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature 552, 253\u2013257 (2017).","journal-title":"Nature"},{"key":"832_CR167","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.xcrm.2023.101053","volume":"4","author":"IY Jung","year":"2023","unstructured":"Jung, I. Y. et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep. Med. 4, 101053 (2023).","journal-title":"Cell Rep. Med."},{"key":"832_CR168","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"832_CR169","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med."},{"key":"832_CR170","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"832_CR171","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","volume":"31","author":"AC Parente-Pereira","year":"2011","unstructured":"Parente-Pereira, A. C. et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31, 710\u2013718 (2011).","journal-title":"J. Clin. Immunol."},{"key":"832_CR172","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-018-0385-z","volume":"6","author":"BO Tschumi","year":"2018","unstructured":"Tschumi, B. O. et al. CART cells are prone to Fas- and DR5-mediated cell death. J. Immunother. Cancer 6, 71 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"832_CR173","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","volume":"129","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N. et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J. Clin. Invest. 129, 1551\u20131565 (2019).","journal-title":"J. Clin. Invest."},{"key":"832_CR174","doi-asserted-by":"publisher","unstructured":"Yamada-Hunter, S. A. et al. Engineered CD47 protects T cells for enhanced antitumor immunity. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.06.20.545790 (2023).","DOI":"10.1101\/2023.06.20.545790"},{"key":"832_CR175","doi-asserted-by":"crossref","first-page":"936496","DOI":"10.3389\/fimmu.2022.936496","volume":"13","author":"T Yu","year":"2022","unstructured":"Yu, T., Yu, S. K., Xiang, Y., Lu, K. H. & Sun, M. Revolution of CAR engineering for next-generation immunotherapy in solid tumors. Front. Immunol. 13, 936496 (2022).","journal-title":"Front. Immunol."},{"key":"832_CR176","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","volume":"40","author":"A Smole","year":"2022","unstructured":"Smole, A. et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell 40, 1470\u20131487.e7 (2022).","journal-title":"Cancer Cell"},{"key":"832_CR177","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413\u2013420 (2010).","journal-title":"Mol. Ther."},{"key":"832_CR178","doi-asserted-by":"crossref","first-page":"100457","DOI":"10.1016\/j.xcrm.2021.100457","volume":"2","author":"T Muliaditan","year":"2021","unstructured":"Muliaditan, T. et al. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep. Med. 2, 100457 (2021).","journal-title":"Cell Rep. Med."},{"key":"832_CR179","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918 (2021).","journal-title":"Nat. Cancer"},{"key":"832_CR180","doi-asserted-by":"crossref","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou, A. et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci. Transl. Med. 13, eabh1962 (2021).","journal-title":"Sci. Transl. Med."},{"key":"832_CR181","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin. Cancer Res. 27, 473\u2013484 (2021).","journal-title":"Clin. Cancer Res."},{"key":"832_CR182","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10097-0","volume":"10","author":"PA Baeuerle","year":"2019","unstructured":"Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).","journal-title":"Nat. Commun."},{"key":"832_CR183","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05395-y","volume":"9","author":"CW Helsen","year":"2018","unstructured":"Helsen, C. W. et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nat. Commun. 9, 3049 (2018).","journal-title":"Nat. Commun."},{"key":"832_CR184","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","volume":"29","author":"R Hassan","year":"2023","unstructured":"Hassan, R. et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results. Nat. Med. 29, 2099\u20132109 (2023).","journal-title":"Nat. Med."},{"key":"832_CR185","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00262-018-2120-5","volume":"67","author":"MJ Scheffel","year":"2018","unstructured":"Scheffel, M. J. et al. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol. Immunother. 67, 691\u2013702 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"832_CR186","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng, W. et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32, 1157\u20131167 (2018).","journal-title":"Leukemia"},{"key":"832_CR187","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).","journal-title":"J. Exp. Med."},{"key":"832_CR188","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1158\/0008-5472.CAN-11-3246","volume":"72","author":"HI Cho","year":"2012","unstructured":"Cho, H. I., Reyes-Vargas, E., Delgado, J. C. & Celis, E. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 72, 1986\u20131995 (2012).","journal-title":"Cancer Res."},{"key":"832_CR189","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-16-1860","volume":"23","author":"CY Slaney","year":"2017","unstructured":"Slaney, C. Y. et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res. 23, 2478\u20132490 (2017).","journal-title":"Clin. Cancer Res."},{"key":"832_CR190","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264\u20131270 (2008).","journal-title":"Nat. Med."},{"key":"832_CR191","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","volume":"31","author":"C Rossig","year":"2017","unstructured":"Rossig, C. et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia 31, 1087\u20131095 (2017).","journal-title":"Leukemia"},{"key":"832_CR192","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1073\/pnas.1614315114","volume":"114","author":"G Xin","year":"2017","unstructured":"Xin, G. et al. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proc. Natl Acad. Sci. USA 114, 740\u2013745 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"832_CR193","doi-asserted-by":"crossref","first-page":"8030440","DOI":"10.1155\/2023\/8030440","volume":"2023","author":"EO Ansah","year":"2023","unstructured":"Ansah, E. O., Baah, A. & Agyenim, E. B. Vaccine boosting CAR-T cell therapy: current and future strategies. Adv. Cell Gene. Ther. 2023, 8030440 (2023).","journal-title":"Adv. Cell Gene. Ther."},{"key":"832_CR194","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"832_CR195","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165.e20 (2023).","journal-title":"Cell"},{"key":"832_CR196","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"832_CR197","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2767-9764.CRC-21-0154","volume":"2","author":"M Birtel","year":"2022","unstructured":"Birtel, M. et al. A TCR-like CAR promotes sensitive antigen recognition and controlled T-cell expansion upon mRNA vaccination. Cancer Res. Commun. 2, 827\u2013841 (2022).","journal-title":"Cancer Res. Commun."},{"key":"832_CR198","doi-asserted-by":"crossref","first-page":"S1404","DOI":"10.1016\/j.annonc.2022.08.035","volume":"33","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A., Haanen, J. B. A. G. & Koenecke, C. BNT211-01: a phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann. Oncol. 33, S1404\u2013S1405 (2022).","journal-title":"Ann. Oncol."},{"issue":"Suppl. 16","key":"832_CR199","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.2023.41.16_suppl.2518","volume":"41","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6 CAR-T cell therapy of relapsed\/refractory solid tumors \u00b1 a CLDN6-encoding mRNA vaccine: dose escalation data from the BNT211-01 phase 1 trial using an automated product [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 2518 (2023).","journal-title":"J. Clin. Oncol."},{"key":"832_CR200","volume":"120","author":"D Mai","year":"2023","unstructured":"Mai, D. et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proc. Natl Acad. Sci. USA 120, e2218632120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"832_CR201","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"832_CR202","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","volume":"196","author":"MA Ligtenberg","year":"2016","unstructured":"Ligtenberg, M. A. et al. Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J. Immunol. 196, 759\u2013766 (2016).","journal-title":"J. Immunol."},{"key":"832_CR203","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"832_CR204","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy, V., Kuehle, J., Hombach, A. A. & Abken, H. CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Mol. Ther. 26, 2218\u20132230 (2018).","journal-title":"Mol. Ther."},{"key":"832_CR205","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","volume":"4","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat. Cancer 4, 1001\u20131015 (2023).","journal-title":"Nat. Cancer"},{"key":"832_CR206","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","volume":"3","author":"E Wang","year":"2015","unstructured":"Wang, E. et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol. Res. 3, 815\u2013826 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"832_CR207","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","volume":"115","author":"S Viaud","year":"2018","unstructured":"Viaud, S. et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc. Natl Acad. Sci. USA 115, E10898\u2013E10906 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"832_CR208","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711\u2013717 (2019).","journal-title":"Blood Adv."},{"key":"832_CR209","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","volume":"28","author":"SA Richman","year":"2020","unstructured":"Richman, S. A. et al. Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Mol. Ther. 28, 1600\u20131613 (2020).","journal-title":"Mol. Ther."},{"key":"832_CR210","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"832_CR211","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ymthe.2023.01.012","volume":"31","author":"M Uribe-Herranz","year":"2023","unstructured":"Uribe-Herranz, M. et al. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Mol. Ther. 31, 686\u2013700 (2023).","journal-title":"Mol. Ther."},{"key":"832_CR212","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas, S. et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76, 1381\u20131390 (2016).","journal-title":"Cancer Res."},{"key":"832_CR213","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","volume":"74","author":"N Nishio","year":"2014","unstructured":"Nishio, N. et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 74, 5195\u20135205 (2014).","journal-title":"Cancer Res."},{"key":"832_CR214","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/mt.2016.137","volume":"24","author":"M Siurala","year":"2016","unstructured":"Siurala, M. et al. Adenoviral delivery of tumor necrosis factor-\u03b1 and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma. Mol. Ther. 24, 1435\u20131443 (2016).","journal-title":"Mol. Ther."},{"key":"832_CR215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","volume":"4","author":"R Havunen","year":"2017","unstructured":"Havunen, R. et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol. Ther. Oncolytics 4, 77\u201386 (2017).","journal-title":"Mol. Ther. Oncolytics"},{"key":"832_CR216","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","volume":"29","author":"R Rezaei","year":"2022","unstructured":"Rezaei, R. et al. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Ther. 29, 647\u2013660 (2022).","journal-title":"Cancer Gene Ther."},{"key":"832_CR217","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","volume":"27","author":"RM Sterner","year":"2020","unstructured":"Sterner, R. M. & Kenderian, S. S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr. Opin. Hematol. 27, 41\u201348 (2020).","journal-title":"Curr. Opin. Hematol."},{"key":"832_CR218","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/0008-5472.CAN-06-2622","volume":"67","author":"A Chen","year":"2007","unstructured":"Chen, A., Liu, S., Park, D., Kang, Y. & Zheng, G. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res. 67, 1291\u20131298 (2007).","journal-title":"Cancer Res."},{"key":"832_CR219","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cancers13081850","volume":"13","author":"J Cinier","year":"2021","unstructured":"Cinier, J. et al. Recruitment and expansion of Tregs cells in the tumor environment \u2013 how to target them? Cancers 13, 1850 (2021).","journal-title":"Cancers"},{"key":"832_CR220","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e11 (2018).","journal-title":"Cell"},{"key":"832_CR221","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","volume":"9","author":"NG Minutolo","year":"2019","unstructured":"Minutolo, N. G., Hollander, E. E. & Powell, D. J. Jr. The emergence of universal immune receptor T cell therapy for cancer. Front. Oncol. 9, 176 (2019).","journal-title":"Front. Oncol."},{"key":"832_CR222","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1021\/jacs.9b11622","volume":"142","author":"NG Minutolo","year":"2020","unstructured":"Minutolo, N. G. et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. J. Am. Chem. Soc. 142, 6554\u20136568 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"832_CR223","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"832_CR224","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3389\/fimmu.2020.01792","volume":"11","author":"B Blanco","year":"2020","unstructured":"Blanco, B., Ramirez-Fernandez, A. & Alvarez-Vallina, L. Engineering immune cells for in vivo secretion of tumor-specific T cell-redirecting bispecific antibodies. Front. Immunol. 11, 1792 (2020).","journal-title":"Front. Immunol."},{"key":"832_CR225","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 11, 599\u2013613 (2021).","journal-title":"Cancer Discov."},{"key":"832_CR226","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488.e6 (2019).","journal-title":"Cancer Cell"},{"key":"832_CR227","volume":"11","author":"NF Kuhn","year":"2020","unstructured":"Kuhn, N. F. et al. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat. Commun. 11, 6171 (2020).","journal-title":"Nat. Commun."},{"key":"832_CR228","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003351","volume":"9","author":"E Conde","year":"2021","unstructured":"Conde, E. et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J. Immunother. Cancer 9, e003351 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"832_CR229","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/2326-6066.CIR-19-0251","volume":"8","author":"G Xin","year":"2020","unstructured":"Xin, G. et al. Pathogen-boosted adoptive cell transfer therapy induces endogenous antitumor immunity through antigen spreading. Cancer Immunol. Res. 8, 7\u201318 (2020).","journal-title":"Cancer Immunol. Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00832-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T09:05:13Z","timestamp":1702976713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00832-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":229,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1038\/s41571-023-00832-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"9 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A. has acted as a scientific adviser to Bio4t2 LLC and Verismo Therapeutics, has received research support from Capstan, Novartis and Tmunity and is a founder of Capstan Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}